EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy

Marianna Fontana iD, Scott D Solomon iD, Jessica Kachadourian, Liron Walsh, Ricardo Rocha, David Lebwohl iD, Derek Smith, Jörg Täubel, Edward J Gane, Björn Pilebro, David Adams, Yousuf Razvi und 8 weitere

New England Journal of Medicine · 12.12.2024 · 391 (23) · 2231-2241

DOI: 10.1056/nejmoa2412309 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 12.12.2024. Verfasst von Marianna Fontana und 19 weiteren Autor:innen. Beteiligte Einrichtung: From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) - both in…. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Genetic Therapy, Prealbumin. Die Arbeit wurde bisher 147-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Supported by Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialCardiomyopathiesGenetic TherapyPrealbuminLiposomesRNA, Guide, KinetoplastidaNanoparticlesAgedAged, 80 and overFemaleHumansMaleMiddle AgedCRISPR-Cas SystemsGene EditingInfusions, IntravenousNatriuretic Peptide, BrainPeptide FragmentsTroponin T

Substanzen

Natriuretic Peptide, BrainPeptide FragmentsPrealbuminpro-brain natriuretic peptide (1-76)Troponin TNTLA-2001LiposomesRNA, Guide, Kinetoplastida

Autor:innen und Institutionen

  • From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) - both in London; Brigham and Women's Hospital, Boston (S.D.S.), and Intellia T…

ORCID-Profile: Marianna Fontana, Scott D Solomon, David Lebwohl

Förderung

  • Supported by Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc.

Zitieren

APA

Fontana, M., Solomon, S. D., Kachadourian, J., Walsh, L., Rocha, R., Lebwohl, D., Smith, D., Täubel, J., Gane, E. J., Pilebro, B., Adams, D., Razvi, Y., Olbertz, J., Haagensen, A., Zhu, P., Xu, Y., Leung, A., Sonderfan, A., Gutstein, D. E., & Gillmore, J. D. (2024). CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. New England Journal of Medicine, 391(23), 2231-2241. https://doi.org/10.1056/nejmoa2412309

Vancouver

Fontana M, Solomon SD, Kachadourian J, Walsh L, Rocha R, Lebwohl D, et al. CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. New England Journal of Medicine. 2024;391(23):2231-2241. doi:10.1056/nejmoa2412309

BibTeX
@article{Fontana2024,
  author = {Fontana, Marianna and Solomon, Scott D and Kachadourian, Jessica and Walsh, Liron and Rocha, Ricardo and Lebwohl, David and Smith, Derek and Täubel, Jörg and Gane, Edward J and Pilebro, Björn and Adams, David and Razvi, Yousuf and Olbertz, Joy and Haagensen, Alexandra and Zhu, Peijuan and Xu, Yuanxin and Leung, Adia and Sonderfan, Alison and Gutstein, David E and Gillmore, Julian D},
  title = {CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {23},
  pages = {2231--2241},
  doi = {10.1056/nejmoa2412309}
}
Kostenlos starten →